(Q38235723)

31 August 2017

title

Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime? (English)

1 reference

31 August 2017

0 references

organ transplantation

1 reference

based on heuristic

inferred from title

cytomegaloviral disease

1 reference

Dante Melendez

1

1 reference

31 August 2017

Raymund R Razonable

series ordinal

2

1 reference

31 August 2017

publication date

31 July 2014

1 reference

Expert Review of Clinical Immunology

31 August 2017

published in

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1213-1227

1 reference

Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Deficient cellular immunity--finding and fixing the defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Human NK cells can control CMV infection in the absence of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Human CD8(+) T-cell differentiation in response to viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Viral immune evasion due to persistence of activated T cells without effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Cellular immune responses to cytomegalovirus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.943190

10.1586/1744666X.2014.943190

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference